CriticalOpioid analgesic, phenylpiperidine class×Selective irreversible monoamine oxidase B inhibitor
Updated · Methodology
Mechanism
Rasagiline strongly and irreversibly inhibits the enzyme monoamine oxidase type B (MAO-B). Monoamine oxidase breaks down catecholamines and serotonin in the nervous system and other tissues (rasagiline label, US Food and Drug Administration, FDA). At recommended doses rasagiline acts selectively on MAO-B, but this selectivity falls as the dose rises above the recommended range (rasagiline FDA label). In people taking MAO inhibitors, including selective MAO-B inhibitors, meperidine has caused serious, sometimes fatal reactions (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA; rasagiline FDA label). The mechanism of these reactions is not fully understood (meperidine FDA label). Rasagiline itself leaves the blood within hours (half-life 0.6–2 hours), but the enzyme inhibition is irreversible, so at least 14 days must pass between stopping rasagiline and the first dose of meperidine (rasagiline SmPC, EMA). Liver enzymes play no part: rasagiline neither inhibits nor induces the main cytochrome P450 enzymes (rasagiline SmPC, EMA), and CYP3A4 and CYP2B6 break down meperidine (meperidine FDA label).
Symptoms
In patients taking monoamine oxidase (MAO) inhibitors, the reaction to meperidine may resemble acute opioid overdose, with coma, severe respiratory depression, cyanosis and low blood pressure. In other cases it brings excitation, seizures, fast heart rate, very high fever and high blood pressure (meperidine label, US Food and Drug Administration, FDA). Serotonin syndrome with rasagiline and meperidine causes confusion, hallucinations, agitation, delirium, headache, coma, fainting, shivering, sweating, fever, high blood pressure, fast heart rate, nausea, diarrhoea, muscle rigidity and twitching, tremor and overactive reflexes with clonus, and it can be fatal (rasagiline FDA label). Symptoms usually start within the first hours or days of combined use but may appear later (meperidine FDA label).
Management
The combination is contraindicated in the rasagiline documents (summary of product characteristics, SmPC, European Medicines Agency, EMA; label, US Food and Drug Administration, FDA) and in the meperidine documents (Spanish SmPC and FDA label). Start meperidine no earlier than 14 days after the last dose of rasagiline (rasagiline SmPC, EMA, and FDA label; meperidine SmPC and FDA label). If another opioid is used instead of meperidine, check it against the rasagiline label too. Under the FDA label, rasagiline is also contraindicated with tramadol, methadone and propoxyphene, although meperidine is the only opioid named in the Spanish rasagiline SmPC. If meperidine has nevertheless been given and signs of serotonin syndrome appear, stop meperidine (meperidine FDA label). Intravenous hydrocortisone or prednisolone have been used for severe reactions, with intravenous chlorpromazine added for high blood pressure and very high fever (meperidine FDA label). The usefulness and safety of opioid overdose reversal agents in this reaction are unknown (meperidine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- AEMPS: Ficha técnica: Petidina (nº registro 89406), sección 4.5 (2026)– AEMPS, CIMA, nº registro 89406, revisión 10/2026, sección 4.5
- FDA: Demerol injection (meperidine) prescribing information (2026)– FDA, DailyMed, Hospira, setid b31d1308-28c3-43f4-e0a6-2f3ed76b8975, revised 07/2026, sections 4, 5.6, 5.8 and 7
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.3 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, información del producto actualizada 08/04/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Petidina, Dolantina 50 mg/ml (nº registro 24245), sección 4.3 (2026)– AEMPS, CIMA, nº registro 24245 (Kern Pharma), revisión 07/2026, secciones 4.3, 4.4 y 4.5